Efficacy, safety and cost of new drugs acting on the central nervous system

European Journal of Clinical Pharmacology

Volumn 59, Issue 1, 2003, Pages 79-84

  Garattini, Silvio ^a   Bertele', Vittorio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Central nervous system drugs; Drug regulation; European market; European Medicines Evaluation Agency; European Public Assessment Report

Indexed keywords

CLOZAPINE; ENTACAPONE; ETIRACETAM; LEVACETYLMETHADOL; LIVER ENZYME; MEMANTINE; OLANZAPINE; PRAMIPEXOLE; RILUZOLE; RIVASTIGMINE; ZALEPLON;

ABDOMINAL PAIN; AGRANULOCYTOSIS; AMINOTRANSFERASE BLOOD LEVEL; AMNESIA; ASTHENIA; CARCINOGENICITY; CENTRAL NERVOUS SYSTEM DISEASE; CONFUSION; DECISION MAKING; DEPERSONALIZATION; DOCUMENTATION; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSKINESIA; FATIGUE; GASTROINTESTINAL SYMPTOM; GENOTOXICITY; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERKINESIA; INSOMNIA; LEUKOPENIA; LIVER DYSFUNCTION; LONG QT SYNDROME; NAUSEA; NEUTROPENIA; ORGANIZATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REBOUND; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUDDEN SLEEP; ULCER; VERTIGO; VISUAL DISORDER; WEIGHT GAIN;

EID: 0038130846     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0569-3     Document Type: Review

References (28)

1. Garattini S, Bertele' V (2002) Efficacy, safety, and cost of new anticancer drugs. BMJ 325:269-271
2. EMEA (1999) Final opinion of the Committee for Proprietary Medicinal Products on the refusal of a marketing authorisation for Kronos. http://www.emea.eu.int/pdfs/human/opinion/06779en.pdf
3. EMEA (2001) Public statement on the recommendation to suspend the marketing authorisation for Orlaam (levacetylmethadol) in the European Union. http://www.emea.eu.int/pdfs/human/press/pus/87760len.pdf
4. Ruottinen HM, Rinne UK (1996) A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 19:283-296
5. Rinne UK, Larsen JP, Siden A, Worm-Petersen J (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 51:1309-1314
6. Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 42:747-755
7. EMEA (2000) European Public Assessment Report on Comtan. http://www.eudra.org/humandocs/humans/epar/comtan/comtan.htm
8. Lieberman A, Ranhosky A, Korts D (1997) Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 49:162-168
9. Guttman M (1997) Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology 49:1060-1065
10. EMEA (2000) European Public Assessment Report on Daquiran. http://www.eudra.org/humandocs/humans/epar/daquiran/Daquiran.htm
11. EMEA (2000) European Public Assessment Report on Exelon. http://www.eudra.org/humandocs/humans/epar/exelon/exelon.htm
12. Qizilbash N, Birks J, Lopez Arrieta J, Lewington S, Szeto S (2002) Tacrine for Alzheimer's disease (Cochrane Review). In: The Cochrane Library, issue 2. Oxford
13. Birks JS, Melzer D, Beppu H (2002) Donepezil for mild and moderate Alzheimer's disease (Cochrane Review). In: The Cochrane Library, issue 2. Oxford
14. EMEA (2002) Committee for Proprietary Medicinal Products. Summary of opinion for Ebixa. http://www.emea.eu.int/pdfs/human/opinion/0055302.pdf
15. Kornhuber J, Weller M (1997) Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 41:135-144
16. EMEA (2002) European Public Assessment Report on Rilutek. http://www.eudra.org/humandocs/humans/epar/rilutek/rilutek.htm
17. Bensimon G, Lacomblez L, Meininger V (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330:585-591
18. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 347:1425-1431
19. Bensimon G, Lacomblez L, Delumeau JC, Bejuit R, Truffinet P, Meininger V (2002) A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol 249:609-615
20. EMEA (2001) European Public Assessment Report on Sonata. http://www.eudra.org/humandocs/humans/epar/sonata/sonata.htm
21. Walsh JK, Fry J, Erwin CW, Scharf M, Roth T, Vogel GW (1998) Efficacy and tolerability of 14-day administration of zaleplon 5 mg and 10 mg for the treatment of primary insomnia. Clinic Drug Invest 16:347-354
22. Elie R, Ruther E, Farr I, Emilien G, Salinas E (1999) Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. J Clin Psychiatry 60:536-544
23. EMEA (2002) European Public Assessment Report on Keppra. http://www.eudra.org/humandocs/humans/epar/keppra/keppra.htm
24. EMEA (2001) European Public Assessment Report on Olansek. http://www.eudra.org/humandocs/humans/epar/olansek/olansek.htm
25. Meltzer HY (2001) Treatment of suicidality in schizophrenia. Ann N Y Acad Sci 932:44-58
26. Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, Revicki DA, and Buchanan RW (2002) Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 325:243-247
27. Vanina Y, Podolskaya A, Sedky K, Shahab H, Siddiqui A, Munshi F, Lippmann S (2002) Body weight changes associated with psychopharmacology. Psychiatr Serv 53:842-847
28. Fontaine KR, Heo M, Harrigan EP, Shear CL, Lakshminarayanan M, Casey DE, Allison DB (2001) Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res 101:277-288